Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers.

MLA

Vogl, Ursula Maria, et al. “Adjuvant Ipilimumab and Nivolumab in Renal Cell Carcinoma: More Questions than Answers.” Lancet, vol. 401, no. 10379, Mar. 2023, pp. 796–98. EBSCOhost, https://doi.org/10.1016/S0140-6736(22)02631-9.

APA

Vogl, U. M., McDermott, D., & Powles, T. (2023). Adjuvant ipilimumab and nivolumab in renal cell carcinoma: more questions than answers. Lancet, 401(10379), 796–798. https://doi.org/10.1016/S0140-6736(22)02631-9

Chicago

Vogl, Ursula Maria, David McDermott, and Thomas Powles. 2023. “Adjuvant Ipilimumab and Nivolumab in Renal Cell Carcinoma: More Questions than Answers.” Lancet 401 (10379): 796–98. doi:10.1016/S0140-6736(22)02631-9.